All In Biotech

Drug Trial Radar · NCT05564390

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Jun 18, 2024

Primary completion

May 15, 2029

Study completion May 15, 2029

Sponsor

Sponsor type
NIH
First posted
Oct 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

Conditions

  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
  • Acute Myeloid Leukemia Post Cytotoxic Therapy
  • Acute Myeloid Leukemia, Myelodysplasia-Related
  • Myelodysplastic Syndrome

Interventions

  • Allogeneic Hematopoietic Stem Cell TransplantationProcedure

    Given IV

  • AzacitidineDrug

    Given IV or SC

  • AzacitidineDrug

    Given IV or SC

  • Best PracticeOther

    Receive SOC treatment

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood, urine, and/or buccal swab samples

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • BusulfanDrug

    Given IV

  • Chest RadiographyProcedure

    Undergo chest x-ray

  • Computed TomographyProcedure

    Undergo CT

  • CytarabineDrug

    Given IV

  • DaunorubicinDrug

    Given IV

  • Daunorubicin HydrochlorideDrug

    Given IV

  • Decitabine and CedazuridineDrug

    Given PO

  • Echocardiography TestProcedure

    Undergo ECHO

  • EmavusertibBiological

    Given PO

  • EnasidenibDrug

    Given PO

  • Epoetin AlfaBiological

    Given SC

  • FludarabineDrug

    Given IV

  • Gemtuzumab OzogamicinDrug

    Given IV

  • GilteritinibDrug

    Given PO

  • Liposome-encapsulated Daunorubicin-CytarabineDrug

    Given IV

  • LuspaterceptBiological

    Given SC

  • MelphalanDrug

    Given IV

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Mutation Carrier ScreeningProcedure

    Undergo rapid genetic testing

  • OlutasidenibDrug

    Given PO

  • Placebo AdministrationDrug

    Given PO

  • Positron Emission TomographyProcedure

    Undergo PET

  • QuizartinibDrug

    Given PO

  • Total-Body IrradiationRadiation

    Undergo total body irradiation

  • VenetoclaxDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignmentTime frame: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy

Locations

360 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Active not recruiting

  • Kaiser Permanente Dublin

    Dublin, California · Recruiting

  • Kaiser Permanente-Fremont

    Fremont, California · Recruiting

  • Kaiser Permanente Fresno Orchard Plaza

    Fresno, California · Recruiting

  • Kaiser Permanente-Fresno

    Fresno, California · Suspended

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • Tibor Rubin VA Medical Center

    Long Beach, California · Active not recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente- Modesto MOB II

    Modesto, California · Recruiting

  • Kaiser Permanente-Modesto

    Modesto, California · Suspended

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Kaiser Permanente-Roseville

    Roseville, California · Recruiting

  • Kaiser Permanente Downtown Commons

    Sacramento, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Kaiser Permanente-South Sacramento

    Sacramento, California · Recruiting

  • Kaiser Permanente-San Francisco

    San Francisco, California · Recruiting

  • UCSF Medical Center-Parnassus

    San Francisco, California · Recruiting

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California · Recruiting

  • Kaiser Permanente San Leandro

    San Leandro, California · Recruiting

  • Kaiser San Rafael-Gallinas

    San Rafael, California · Recruiting

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California · Recruiting

  • Kaiser Permanente-Santa Rosa

    Santa Rosa, California · Recruiting

  • Kaiser Permanente-South San Francisco

    South San Francisco, California · Recruiting

  • Kaiser Permanente-Vallejo

    Vallejo, California · Recruiting

  • Kaiser Permanente-Walnut Creek

    Walnut Creek, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Veterans Affairs Connecticut Healthcare System-West Haven Campus

    West Haven, Connecticut · Recruiting

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Memorial Hospital West

    Pembroke Pines, Florida · Recruiting

  • Moffitt Cancer Center at SouthShore

    Ruskin, Florida · Recruiting

  • Moffitt Cancer Center-International Plaza

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center - McKinley Campus

    Tampa, Florida · Recruiting

Showing 40 of 360 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.